Blood-Based Epigenetic Protein EpiScores Enhance Prognosis of Colorectal Cancer Recurrence and Survival

Blood-based epigenetic signals linked to immune activity, angiogenesis, and coagulation are showing promise as prognostic markers after a colorectal cancer diagnosis. New research reports that adding select “protein epiScores” derived from DNA methylation in whole blood to standard clinical information sharpened predictions of who is more likely to recur or die following treatment, pointing to a potential low-burden tool that could help health systems stratify risk and plan follow-up more precisely.

A blood-based epigenetic signature tied to recurrence and survival

• Protein epiScores quantify DNA methylation patterns in circulating immune cells that correlate with particular protein pathways, offering a snapshot of a patient’s underlying immune and inflammatory state at the time of diagnosis.
• Four epiScores — HCII, VEGFA, CCL17, and LGALS3BP — were linked with a 60%–70% higher risk of recurrence; the LGALS3BP score was also associated with an 80% higher risk of death during follow-up.
• When combined with stage and other routine factors, prediction for disease-free survival improved from a C-index of 0.64 to 0.70; for overall survival, from 0.70 to 0.75, indicating a modest but statistically significant gain over standard clinicopathologic risk models.

What the scientists say

“We wanted to know whether a new blood-based test could better identify colorectal cancer patients at higher risk for recurrence or death. Doctors typically rely on tumor and patient characteristics, but those factors do not fully explain why patients with similar profiles can have very different outcomes. We tested whether protein epiScores could add useful information beyond standard clinical factors.”

“Protein epiScores are based on DNA methylation patterns in blood cells. They act like a fingerprint of the immune cell’s state related to certain protein signals, rather than measuring protein levels directly. We used them because protein levels can fluctuate from day to day, while DNA methylation patterns tend to be more stable over time.”

“Using only traditional clinical factors, our model predicted recurrence with about 64% accuracy. Adding the four key protein epiScores increased accuracy to 70%. For overall survival, accuracy improved from 70% to 75% when the LGALS3BP score was added.”

“We also saw improved risk classification, with more accurate prediction for 34% of patients for recurrence and 16 percent for mortality. Unfortunately, we were lacking information from circulating tumor DNA, so we will need to account for that in future studies, but even the small improvements shown here can have meaningful clinical impact.”

“These findings suggest protein epiScores could eventually be incorporated into tools that help guide treatment and follow-up decisions. More broadly, the study shows that useful prognostic information can be obtained from a simple blood draw taken before treatment begins. Because these scores reflect relatively stable immune characteristics, they may help explain why some patients have poorer outcomes. However, the findings must be validated in other populations before clinical use.”

How a prognostic blood test could be used by health systems

• Risk-adapted surveillance planning after curative-intent treatment — for example, tailoring visit cadence, colonoscopy intervals, or imaging intensity according to predicted recurrence risk, while remaining aligned with national guideline baselines.
• Multidisciplinary case review inputs alongside pathology, stage, margin status, and molecular features, helping tumor boards refine prognostic discussions and shared decision-making without substituting for guideline-directed care.
• Population management and service planning: prioritizing navigation and care-coordination resources for higher-risk groups, informing capacity planning for surveillance imaging, and potentially reducing unnecessary utilization for lower-risk patients where appropriate.

Implementation guardrails and evidence standards

• Analytical and clinical validity must be demonstrated across diverse cohorts; the initial cohort here was predominantly White, underscoring the need for broader external validation in community settings and across health systems before any routine deployment.
• Clinical utility requires prospective evidence that incorporating epiScores changes management in ways that improve patient outcomes, equity, or resource efficiency compared with existing risk models alone.
• Careful positioning versus emerging circulating tumor DNA (ctDNA)–based tools, which can also inform prognosis and treatment monitoring, will be essential to avoid duplicative testing and to clarify where a stable baseline immune “fingerprint” adds value over dynamic tumor-derived markers.

Policy and market context for blood-based tests

• Screening vs. prognosis: Regulatory and coverage pathways differ. A blood-based colorectal cancer screening test received U.S. Food and Drug Administration approval on July 26, 2024, becoming an option for average‑risk adults aged 45 and older; Medicare covers certain blood-based biomarker screening tests once every three years under preventive services when criteria set in the Social Security Act’s Medicare benefit definitions are met. By contrast, prognostic assays like protein epiScores are typically introduced as laboratory-developed tests or companion diagnostics linked to treatment decisions.
• LDT landscape: A federal district court vacated FDA’s 2024 final rule to regulate laboratory‑developed tests on March 31, 2025, and the agency subsequently formalized vacatur in September 2025. As of February 16, 2026, most LDTs remain primarily overseen under the Clinical Laboratory Improvement Amendments (CLIA), shaping how novel prognostic assays might initially reach patients and what levers regulators and payers can use to demand evidence.
• Guideline and payer adoption: For a prognostic assay to influence care pathways, endorsing bodies and insurers typically seek multi-site validation, demonstrated clinical utility, and clear cost-effectiveness within standard follow-up frameworks, including impacts on imaging use, emergency presentations, and late-stage recurrences.

Population-level relevance without clinical overreach

• Colorectal cancer is the second leading cause of cancer death in the U.S. when men and women are combined, so even incremental improvements in risk prediction can translate into meaningfully fewer late recurrences and potentially more efficient use of oncology resources at scale.
• Blood-based tools may lower patient burden and enable more equitable access to prognostic information if validated and integrated responsibly, particularly in regions where advanced imaging or specialty follow-up is constrained. At the same time, adoption should avoid diverting resources from proven screening, early detection, and treatment services that remain the primary levers for reducing mortality.

Key dates and milestones

• February 1, 2026: Study on protein epiScores and colorectal cancer survival published in Clinical Epigenetics, marking one of the first long-term evaluations of DNAm-predicted protein signals as post-diagnosis prognostic markers.
• February 9, 2026: Research summary released by a comprehensive cancer center, positioning the work as a potential foundation for future blood-based prognostic tools.
• July 26, 2024: FDA approval of a blood-based colorectal cancer screening test as a primary option for average‑risk adults; Centers for Medicare & Medicaid Services (CMS) preventive coverage applies under existing policy for qualifying beneficiaries.
• March 31, 2025 / September 19, 2025: Federal court vacates FDA’s LDT rule; FDA later formalizes vacatur, reinforcing CLIA-centered oversight for novel lab-developed prognostic assays and leaving Congress and regulators to decide whether a new legislative framework is needed.